Laurate biosensors image brain neurotransmitters in vivo: Can an antihypertensive medication alter psychostimulant behavior?

Sensors

Volumn 8, Issue 7, 2008, Pages 4033-4061

  Broderick, Patricia A ^a,b,c   Ho, Helen ^a   Wat, Karyn ^a   Murthy, Vivek ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Brain; Caffeine; Cocaine; Dopamine; Electrochemistry; G protein receptor complexes (GPRC); Homovanillic acid; Hypertension; Ketanserin; L tryptophan; Mesolimbic; Motor tracts; Neuromolecular imaging; Nucleus accumbens; Open field behaviors; Psychostimulants

Indexed keywords

ANXIETY; COCAINE; DOPAMINE; HOMOVANILLIC ACID; HYPERTENSION; KETANSERIN; L-TRYPTOPHAN; MESOLIMBIC; NUCLEUS ACCUMBENS; OPEN-FIELD BEHAVIORS; PSYCHOSTIMULANTS; RECEPTOR COMPLEX;

ACTIVATION ANALYSIS; AMINES; AMINO ACIDS; BRAIN; CAFFEINE; ELECTROCHEMISTRY; ELECTRON TRANSITIONS; NEURONS; PROBES; PROTEINS;

BIOSENSORS;

EID: 48749132132     PISSN: 14248220     EISSN: None     Source Type: Journal    
DOI: 10.3390/s8074033     Document Type: Article

References (90)

1. Khan, A.S.; Michael, A.C. Invasive consequences of using microelectrodes and microdialysis probes in the brain. Trends in Anal.Chem. 2003, 22, 503-508.
2. Phelix, C.F.; Broderick, P.A. Light microscopic immunocytochemical evidence of converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. Brain Res. Bull. 1995, 37, 37-40.
3. Jacobs, B.L; Azmitia, E.C. Structure and function of the brain serotonin system. Physiol. Rev. 1992, 72, 165-229.
4. Koob, G.F.; Nestler, E.J. The neurobiology of drug addiction. J. Neuropsychiatry, Clinical Neuroscience 1997, 9, 482-497.
5. Keiflin, R.; Isingrini, E.; Cador, M. Cocaine-induced reinstatement in rats: evidence for a critical role of cocaine stimulus properties. Psychopharmacology (Berl.) 2008, (Epub ahead of print).
6. Filip, M; Frankowska, M.; Zaniewska, M.; Przegalinski, E.; Muller, C.E.; Agnati, L.; Franco, R.; Roberts, D.C.; Fuxe, K. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res. 2006, 1077, 67-80.
7. Broderick, P.A.; Hope, O.; Okonji, C.; Rahni, D.N.; Zhou, Y. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal. Prog. Neuropsychopharmacol. Biol. Psychiat. 2004, 28, 157-171.
8. Solinas, M.; Ferre, S.; You, Z.B.; Karcz-Kubicha, M.; Popoli, P.; Goldberg, S.R. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J. Neuroscience 2002, 22, 6321-6324.
9. Weinberg, B.A.; Bealer, B.K. The World of Caffeine; Routledge: New York and London, 2001. ISBN-0-415-92722-6.
10. Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; Liu, X.; Zhu,P.; Chen, J-F; Zhou, Y. Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Neuroscience 2008, 4, 1198-1207.
11. Campbell, R.; Burchfield, G.; Hopes, M.; Mitchell, J. ABC ONLINE; Australian Broadcasting System, 1997.
12. Salazar-Martinez, E.; Willet, W.C.; Ascherio, A.; Manson, J.E.; Leitzmann, M.F.; Stampfer, M.J.; Hu, F.B. Coffee consumption and risk for type 2 diabetes mellitus. Ann. Internal Med. 2004, 140, 1-8.
13. Xu, K.; Xu, Y.; Brown-Jermyn, D.; Chen, J-F; Ascherio, A.; Diuzen, D.; Schwarzschild, M.A. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's Disease. Neurobiology of Disease, J. Neuroscience 2006, 26, 515-541.
14. van der Starre, P.J.; Reneman, R.S. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade. J. Cardiovasc. Pharmacol. 1988, 11, S54-S61.
15. Duffy, R.A.; Hunt, M.A.; Wamsley, J.K.; McQuade, R.D. In vivo autoradiography of [3H] SCH 39166 in rat brain: selective displacement by D1/D5 antagonists. J. Chem. Neuroanat. 2002, 19, 41-46.
16. Lutje -Hulsik, D. Functional and Binding Data for Ketanserin Tartrate. Organon GPCRDB, 2002.
17. Cazzola, M.; Matera, M.G.; Santangelo, G.; Assogna, G.; D'Amato, G.; Rossi, F.; Girbino, G. Effect of the selective 5-HT2 antagonist ketanserin on adenosine-induced bronchoconstriction in asthmatic patients. Immunopharmacology 1992, 23, 21-28.
18. Hubbard, A.T.; Anson, F.C. Electroanalytical Chemistry; Bard, Alan J., Ed.; Marcel Dekker: New York, 1970; Volume V.
19. Adams, R.N.; Marsden, C.A. New techniques in psychopharmacology. In Handbook of Psychopharmacology; Iversen, L.L, Snyder, S.H, Eds.; Plenum Press: New York, 1982.
20. Kissinger, P.T.; Preddy, C.R.; Shoup, R.E.; Heineman, W.R. Fundamental concepts of analytical electochemistry. In Laboratory Techniques in Electroanalytical Chemistry; Kissinger, P.T., Heineman, W. R., Eds.; Marcel Dekker Inc.: New York, 1996; pp. 11-50.
21. Broderick, P.A. Distinguishing in vitro electrochemical signatures for norepinephrine and dopamine. Neurosci Lett 1988, 95, 275-280.
22. Broderick, P.A. Cathodic Electrochemical Current Arrangement with Telemetric Application. 1989(a), U.S. Patent # 4, 883,057.
23. Broderick, P.A. Characterizing stearate probes in vitro for the electrochemical detection of dopamine and serotonin. Brain Res. 1989(b), 495, 115-121.
24. Broderick, P.A. Microelectrodes and their use in cathodic electrochemical current arrangement with telemetric application. 1995, U.S. Patent # 5,433,710.
25. Broderick, P.A. Microelectrodes and their use in an electrochemical arrangement with telemetric application. 1999, U.S. Patent # 5, 938, 903.
26. Broderick, P.A.; Pacia, S.V. Identification, diagnosis, and treatment of neuropathologies, neurotoxicities, tumors and brain and spinal cord injuries using microelectrodes with microvoltammetry. 2006, U.S. Patent # 7,112,319.
27. Garris, P.A.; Christensen, J.R.C.; Rebec, G.V.; Wightman, R.M. Real-time measurement of electrically evoked extracellular dopamine in the striatum of freely moving rats. J. Neurochem. 1997, 68, 152-161.
28. David, D.J.; Zahniser, N.R.; Hoffer, B.J.; Gerhardt, G.A. In vivo electrochemical studies of dopamine clearance in subregions of rat nucleus accumbens: differential properties of the core and shell. Exp. Neurol. 1998, 153, 277-286.
29. Kane, D.A.; O'Neill, R.D. Major differences in the behavior of carbon paste and carbon fibre electrodes in a protein-lipid matrix: Implications for voltammetry in vivo. Analyst 1998, 123, 2899-2903.
30. Foucault, R.; Broderick, P.A.; Rahni, D.N.; Lombardi, J.R.; Birke, R.L. Neurotransmitter signatures: a correlation between Raman spectroscopy and the microvoltammetric BRODERICK PROBE®, 2002; NIH/NIGMS Symposium, New Orleans, LA.
31. Broderick, P.A. Studies of oxidative stress mechanism using a morphine/ascorbate animal model and novel N-stearoyl cerebroside and laurate sensors. J. Neural Transm. 2008, 115, 7-17.
32. Coury, L.A.; Huber, E.W.; Heineman, W.P. Applications of modified electrodes in the voltammetric determination of catecholamine neurotransmitters. Biotechnology 1989, 11, 1-37.
33. Broderick, P.A.; Pacia, S.V.; Doyle, W.K.; Devinsky, O. Monoamine neurotransmitters in resected hippocampal subparcellations from neocortical and mesial temporal lobe epilepsy patients: in situ microvoltammetric studies. Brain Res. 2000, 878, 49-63.
34. Broderick, P.A.; Pacia, S.V. Imaging white matter signals in epilepsy patients: A unique sensor technology. In Bioimaging in Neurodegeneration; Broderick, P.A., Rahni, D.N., Kolodny, E.H., Eds.; Humana Press Inc.: Totowa, NJ, 2005; pp. 199-206.
35. Pellegrino, L.J.; Pellegrino, A.S.; Cushman, A.J. A Stereotaxic Atlas of the Rat Brain; Plenum Press: New York, 1979.
36. Teitelbaum, P.; Pellis, S.M.; De Vietti, T.L. Disintegration into stereotypy induced by drugs or brain damage: a microdescriptive behavioral analysis. In Neurobiology of Stereotyped Behavior; Cooper, S.J., Dourish, S.T., Eds.; Oxford University Press: New York, 1990; pp. 169-199.
37. Simon, P.; Dupuis, R..; Costentin, J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmission. Behavioural Brain Research. 1994, 61, 59-64.
38. Geyer, M.A.; Russo, P.V.; Masten, V.L. Multivariate assessment of locomotor behavior: pharmacological and behavioral analysis. Pharmacol. Biochem. Behav. 1986, 277-288.
39. Mallo, T.; Alttoa, A.; Koiv, K.; Tonissaar, M.; Eller, M.; Harro, J. Rats with persistently low or high exploratory activity: behaviour in tests of anxiety and depression, and extracellular levels of dopamine. Behavioral Brain Res. 2007, 177, 269-281.
40. Broderick, P.A.; Phelix, C.F.I. Serotonin (5-HT) within dopamine reward circuits signals open-field behavior. II. basis for 5-HT-DA interaction in cocaine dysfunctional behavior. Brain Res. Bull. 1997, 21, 227-260.
41. Chin, J.; Sternin, O.; Fletcher, H.; Jenab, S.; Perrotti, L.I.; Quinones-Jenab, V. Sex differences in cocaine-induced behavioral sensitization. Cell. Mol. Biol. 2001, 47, 1089-1095.
42. Kosten, T.R.; Kosten, T.A.; McDougle, C.J.; Hameedi, F.A.; McCance, F.F.; Rosen, M.I. Gender differences in response to intranasal cocaine administration in humans. Biological Psychiat. 1996, 39, 147-148.
43. Nunes, J.; Broderick, P.A. Novel research translates to clinical cases of schizophrenia and cocaine psychosis. Neuropsychiatric Disease and Treatment. 2007, 3, 475-486.
44. Broderick, P.A.; Kornak, E.P.; Eng, F.; Wechsler, R. Real time detection of acute (IP) cocaine-enhanced dopamine and serotonin release in ventrolateral nucleus accumbens of the behaving Norway rat. Pharmacol Biochem Behav. 1993, 46, 715-722.
45. Carlsson, A.; Carlsson, M.L. Dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin. Neurosci. 2006, 8, 1370142.
46. Bubar, M.J.; Cunningham, K.A. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr. Top. Med. Chem. 2006, 6, 1971-1985.
47. Henry, L.K.; Blakely, R.D. Distinctions between dopamine transporter antagonists could be just around the bend. Mol. Pharmacol. 2008, 73, 616-618.
48. Marcellino, D.; Roberts, D.C.S.; Navarro, G.; Filip, M.; Agnati, L.; Lluis, C.; Franco, R.; Fuxe, K. Increase in A2A receptors in the nucleus accumbens after extended cocaine self-administration and its disappearance after cocaine withdrawal. Brain Res. 2007, 1143, 208-220.
49. Zelek-Molik, A.; Kreiner, G.; Roman, A.; Bielawski, A.; Nalepa, I. Effect of repeated cocaine administration on the mRNAs expression of main classes of G alpha proteins in the rat brain. Eur. Neuropsychopharmacol. 2006, 16 (Suppl. 1), S8-S9.
50. Thomas, M.J.; Kalivas, P.W.; Shaham, Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br. J. Pharmacol. 2008, 154, 327-342.
51. Griffiths, R.R.; Mumford, G.K. Caffeine: A drug of abuse? Neuropsychopharmacology, The Fifth Generation of Progress, 2000. http://www.acnp.org/G4/GN401000165/CH161.html
52. Weerts, E.M.; Griffiths, R.R. The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology (Berl.) 2003, 168, 155-163.
53. Franco, R.; Casado, V.; Cortes, A.; Mallol, J.; Ciruela, F.; Ferre, S.; Lluis, C.; Canela, E.I.; G-protein coupled receptor heteromers: function and ligand pharmacology. Br. J. Pharmacol. 2008, 153, 590-598.
54. Ward, R.P.; Dorsa, D.M. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration. Neurosci. 1999, 89, 927-938.
55. Rashid, A.J.; O'Dowd, B.F.; Verma, V.; George, S.R.; Neuronal Gq/11-coupled dopamine receptors: an uncharted role for dopamine. Trends in Pharmacol. Sci. 2007, 28, 551-555.
56. Daly, J.W.; Fredholm, B.B. Caffeine-an atypical drug of dependence. Drug Alcohol Depend. 1998, 55, 199-206.
57. Fredholm, B.B. ; Battig, K. ; Holmen, J. ; Nehlig, A.; Zvartau, E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999, 55, 88-133.
58. Solinas, M.; Ferre, S.; Antoniou, K.; Quarta, D.; Justinova, Z.; Hockemeyer, J.; Pappas, L.A.; Segal, P.N.; Wertheim, C.; Muller, C.E.; Goldberg, S.R. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology (Berl.) 2005, 179, 576-586.
59. Ciruela, F.; Casado, V.; Rodrigues, R.J.; Lujan, R.; Burgueno, J.; Canals, M.; Borycz, J.; Rebola, N.; Goldberg, S.R.; Mallol, J.; Cortes, A.; Canela, E.I.; Lopez-Gimenez, J. F.; Milligan, G.; Lluis, C.; Cunha, R.A.; Ferre, S.; Franco, R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 2006, 26, 2080-2087.
60. Ciruela, F.; Ferre, S.; Casado, V.; Cortes, A.; Cunha, R.A.; Lluis, C.; Franco, R. Heterodimeric adenosine receptors: a device to regulate neurotransmitter release. Cell.Mol.Life Sci. 2006, 63, 2427-2431.
61. Capper-Loup, C.; Canales, J.J.; Kadaba, N.; Graybiel, A.M.; Concurrent activation of dopamine D1and D2 receptors is required to evoke neural and behavioral phenotypes of cocaine sensitization. J.Neurosci. 2002, 6218-6227.
62. Broderick, P.A.; Medicherla, R.; Zhou, F.; Forrester, L.W. Imaging accumbens monoamines with behavior: ketanserin, caffeine and cocaine interactions. Society for Neuroscience 2005, Wash. D.C., November 12-16.
63. Horger, B.A.; Wellman, P.J.; Morien, A.; Davies, B.T.; Schenk, S. Caffeine exposure sensitizes rats to the reinforcing effects of cocaine. Neuroreport 1991, 2, 53-56.
64. Schenk, S.; Worley, C.M.; McNamara, C.; Valadez, A. Acute and repeated exposure to caffeine: effects on reinstatement of extinguished cocaine-taking behavior in rats. Psychopharmacology 1996, 126, 17-23.
65. Carroll, M.E.; Lac, S.T. Dietary additives and the acquisition of cocaine self-administration in rats. Psychopharmacology 1998, 137, 81-89.
66. Broderick, P.A; Ho.H.; Huang, J.; Wat, K.; Shahidullah, J.; Murthy, V.; Wenning, L.; Buchheim, L. Caffeine may neuroprotect against cocaine-induced dopamine release in accumbens of female rats. Society for Neuroscience 2007, San Diego, CA, November 3-7.
67. Nesbitt, J.; Raju, C.; Vidal, L.; Alimova, A.; Steiner, J.; Broderick, P.A.; Friedman, E. Sexual dimorphism studies of cocaine and caffeine in conditioned place preference: estrous cycle stage and open-field behaviors. Society for Neuroscience 2008, Wash, D.C., November 15-19.
68. Schiffman, S.N.; Fisone, G.; Moresco, R.; Cunha, R.A.; Ferre, S. Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 2007, 63, 277-292.
69. Leysen, J.E.; Gommeren, W.; Schotte, A. Serotonin receptor subtypes: possible roles and implications in antipsychotic drug action. In Serotonergic Mechanisms in Antipsychotic Treatment; Kane, J.M., Moller, H.-J., Awouters, F., Eds.; Marcel-Dekker: New York, 1996; pp.51-76.
70. Gleerup, G.; Persson, B.; Hedner, T.; Winther, K. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists. Eur J Clin Pharmacol 1993, 44, 121-125.
71. Mandhane, S.N.; Khisti, R.T.; Chopde, C.T. Effect of serotonergic agents on adenosine A2 receptor mediated catalepsy in rats. Psychopharmacology (Berl.) 1998, 137, 113-119.
72. Shi, J.; Damjanoska, K.J.; Singh, R.K.; Carrasco, G.A.; Garcia, F.; Grippo, A.J.; Landry, M.; Sullivan, N.R.; Battaglia, G.; Muma, N.A. Agonist induced-phosphorylation of Galpha11 protein reduces coupling to 5-HT2A receptors. J. Pharmacol. Exp. Ther. 2007, 323, 248-256.
73. Adlersberg, M.; Arango, V.; Hsiung, S.; Mann, J.J.; Underwood, M.D.; Liu, K.; Kassir, S.A.; Ruggiero, D.A.; Tamir, H. In vitro autoradiography of serotonin 5-HT(2A/2C) receptor-activated G protein: guanosine-5′-(gamma- [(35)S]thio)triphosphate binding in rat brain. J. Neurosci. Res. 2000, 61, 674-685.
74. McMahon, L.R.; Cunningham, K.A. Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J. Pharmacol. Exp.Ther. 2001, 297, 357-363.
75. Broderick, P.A.; Olabisi, O.A.; Rahni, D.N.; Zhou, Y. Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies. Prog. Neuropsychopharmacol. Biol. Psychiat. 2004, 28, 547-557.
76. Schindler, C. Cocaine and cardiovascular toxicity. Addict. Biol. 1996, 1, 31-47.
77. Knuepfer, M.M. Muscarinic cholinergic and beta-adrenergic contribution to hindquarters vasodilation and cardiac responses to cocaine. J. Pharmacol. Exp. Ther. 2003, 306, 515-522.
78. Miao, C.Y.; Yuan, W.J.; Su, D.F. Comparative study of sinoaortic denervation rats and spontaneously hypertensive rats. Am. J. Hypertension 2003, 16, 585-591.
79. Kirouac, G.J.; Ganouly, P.K. Up-regulation of dopamine receptors in the brain of the spontaneously hypertensive rat: an autoradiographic study. Neuroscience 1993, 52, 135-141.
80. Kirouac, G.J.; Ganouly, P.K. Cholecystokinin-induced release of dopamine in the nucleus accumbens of the spontaneously hypertensive rat. Brain Res. 1995, 689, 245-253.
81. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; Molina, P.E.; Logan, J.; Gatley, S.J.; Gifford, A.; Ding, Y.S.; Wong, C.; Pappas, N.R.; Zhu, W.; Swanson, J.M. Cardiovascular effects of methylphenidate in humans associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl.) 2003, 166, 264-270.
82. Toda, S.; Alguacil, L.F.; Kalivas, P.W. Repeated cocaine administration changes the function and subcellular distribution of adenosine A1 receptor in the rat nucleus accumbens. J. Neurochem. 2003, 86, 1478-1484.
83. Bowers, M.S.; McFarland, K.; Russell, W.L.; Peterson, Y.K.; Lapish, C.C.; Gregory, M.L.; Lanier, S.M.; Kalivas, P.W. Activator of G protein signalling 3 A gatekeeper of cocaine sensitization and drug seeking. Neuron 2004, 42, 269-281.
84. McGinty, J.F.; Shi, X.D.; Schwendt, M.; Saylor, A.; Toda, S. Regulation of psychostimulant-induced signaling and gene expression in the striatum. J. Neurochem. 2008, 104, 1440-1449.
85. Harvey, J.A.; Romano, A.G.; Gabriel, M.; Simansky, K.J.; Du, W.; Aloyo, V.J.; Friedman, E. Effects of prenatal exposure to cocaine on the developing brain: anatomical, chemical, physiological and behavioral consequences. Neurotox. Res. 2001, 3, 117-143.
86. Svenningsson, P.; Nishi, A.; Fisone, G.; Girault, J.-A.; Nairn, A.C.; Greengard, P. DARPP-32: An integrator of neurotransmission. Ann. Rev. Pharmacol. Toxicol. 2004, 269-296.
87. Broderick, P.A.; Li, Y-S.; Ho, H.; Wat, K.; Haile, M.M.; Bekker, A.Y.; Kolodny, E.H. Neuromolecular imaging of monoamine and peptide neurotransmitters in an animal model of Parkinson's disease: effects of the dopamine agonist, bromocriptine. Society for Neuroscience 2008, Wash. D.C., November 15-19.
88. Haile, M.M.; Broderick, P.A.; Li, Y-S.; Quartermain, D.; Blanck, T.J.J; Bekker, A.Y. Nimodipine reverses the hypoxia-induced elevation of dopamine and serotonin in striatum of adult rats. American Society of Anesthesiologists 2008, Orlando, FL., October 18-22.
89. Laviolette, S.R.; van der Kooy, D. The neurobiology of nicotine addiction: bridging the gap from molecules to behavior. Nature Reviews Neuroscience 2004, 55-65. http://www.nature.com/nrn/journal/v5/n1/ fig_tab/nrn1298_F2.html
90. Swanson, L.W. The projections of the ventral tegmental area and adjacent regions: a combined retrograde tracer and immunofluourescence study in the rat. Brain Res. Bull. 1982, 9, 321-353.